With Urinary Urgency vs Without Urinary Urgency: Risk Factors for the Proportion of Responders of Tolterodine-Urinary Urgency
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.848 | 0.839 | 0.856 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.795 | 0.769 | 0.818 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.0531 | 0.028 | 0.08 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.07 | 1.03 | 1.1 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.44 | 1.22 | 1.7 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on With Urinary Urgency than on Without Urinary Urgency | 18.8 | 12.5 | 35.7 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | With Urinary Urgency | Participants with urinary urgency who took tolterodine according to Japanese Package Insert. | 5,529 | 6,521 | OG000 | ClinicalTrials.gov |
| Group 2 | Without Urinary Urgency | Participants without urinary urgency who took tolterodine according to Japanese Package Insert. | 829 | 1,043 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Risk Factors for the Proportion of Responders of Tolterodine-Urinary Urgency | ClinicalTrials.gov |
| Description | Number of participants with responders of tolterodine to determine whether with or without Urinary urgency is significant risk factor. | ClinicalTrials.gov |
| Time frame | 12 week | ClinicalTrials.gov |
| Population | The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately). | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan) | ClinicalTrials.gov |
| NCT number | NCT01488578 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Overactive Bladder | ClinicalTrials.gov |
| Interventions | Tolterodine tartrate | ClinicalTrials.gov |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | ClinicalTrials.gov |
| Results first posted | 2012-06-14 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT01488578?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.